Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines

Epidermal growth factor receptor (EGFR) is a well-validated oncological target molecule for monoclonal antibody therapies and Sym004 is a novel anti-EGFR antibody mixture comprising two recombinant chimeric IgG1 antibodies against non-overlapping epitopes of EGFR. Because EGFR is highly expressed in...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Fukuoka, Shota, Kojima, Takashi, Koga, Yoshikatsu, Yamauchi, Mayumi, Komatsu, Masayuki, Komatsuzaki, Rie, Sasaki, Hiroki, Yasunaga, Masahiro, Matsumura, Yasuhiro, Doi, Toshihiko, Ohtsu, Atsushi
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355242/
https://ncbi.nlm.nih.gov/pubmed/28038457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14209
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items